Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)
Vor Biopharma Price Target Maintained With a $12.00/Share by JMP Securities
Evercore Initiates Vor Biopharma(VOR.US) With Buy Rating
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Vor Biopharma Analyst Ratings
Barclays Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $3
Vor Biopharma (VOR) Receives a Buy From Barclays
Promising Clinical Outcomes and Strategic Acquisitions Bolster Buy Rating for Vor Biopharma
Vor Biopharma Analyst Ratings
Barclays Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $3
Vor Biopharma (VOR) Receives a Buy From Barclays
Buy Rating Backed by Clinical and Financial Strengths at Vor Biopharma
Wedbush Keeps Their Buy Rating on Vor Biopharma (VOR)
Optimistic Outlook on Vor Biopharma's Pipeline and Financial Stability Drives Buy Rating
Positive Outlook for Vor Biopharma: Strong Financials and Promising Clinical Trials Underpin Buy Rating
Buy Rating Affirmed for Vor Biopharma Amid Promising Clinical Trials and Market Potential Expansion
Buy Rating Affirmed: Vor Biopharma's Clinical and Financial Fortitude
J.P. Morgan Securities: The Vor Biopharma (VOR.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $12.00.
Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating
Vor Biopharma Analyst Ratings